Home / Recalls / Preferred Pharmaceuticals, Inc. / D-0391-2025

D-0391-2025 Class II Ongoing

Recalled by Preferred Pharmaceuticals, Inc. — Anaheim, CA

Recall Details

Product Type
Drugs
Report Date
May 7, 2025
Initiation Date
April 18, 2025
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1190 Bottles

Product Description

Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.

Reason for Recall

cGMP Deviations

Distribution Pattern

Nationwide in the US

Code Information

Lot #: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, L2324L, Exp: 7/31/2026.

Other recalls by Preferred Pharmaceuticals, Inc.

  • D-0239-2026 Class II — Ondansetron ODT Tablets, USP 4mg, 1x10 unit dose tablets, Mfg: Glenmark Pharmac (November 17, 2025)
  • D-0647-2024 Class II — Ibuprofen Tablets, USP 400mg, Generic for Motrin, Pkg Size: 30 tablets per bottl (August 8, 2024)
  • D-0505-2024 Class II — Duloxetine Delayed-Release Cap USP 30mg, 30-count bottle, Rx only, Preferred Pha (May 10, 2024)
  • D-0894-2023 Class II — Tizanidine Hydrochloride Tablet 4mg, packaged in a) 20 count-bottles (NDC 68788- (June 26, 2023)
  • D-0504-2023 Class II — Alprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceu (March 27, 2023)
  • D-0505-2023 Class II — Alprazolam Tab, USP 0.5mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-759 (March 27, 2023)
  • D-0506-2023 Class II — Alprazolam Tab, USP 1mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7596- (March 27, 2023)
  • D-0511-2023 Class II — Atorvastatin Calcium Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured (March 23, 2023)
  • D-0514-2023 Class II — Doxazosin Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured: Accord He (March 23, 2023)
  • D-0515-2023 Class II — Doxazosin Tablets, USP, 4 mg, 100-count bottle, Rx only, Manufactured: Accord He (March 23, 2023)